Table 1 Baseline and stimulation characteristics of patients in group without (Group A) and with (Group B) pretreatment with Myo-inositol
No myo-inositol | Yes myo-inositol | p | |
|---|---|---|---|
Group A | Group B | ||
N = 50 | N = 50 | ||
No. of patients | 50 | 50 | |
Age (year) | 33.3 ± 2.8 | 34.4 ± 3.4 | 0.09 |
BMI | 22.9 ± 3.3 | 22.7 ± 2.6 | 0.88 |
FSH (mIU/ml), basal | 7.3 ± 1.5 | 7.2 ± 2 | 0.35 |
LH (mIU/ml), basal | 4.7 ± 2 | 4.9 ± 2 | 0.87 |
17β-estradiol (E2) (pg/ml), | 47.2 ± 17.8 | 43.6 ± 12.7 | 0.20 |
basal | |||
FSH (mIU/ml), down | 4.7 ± 1.5 | 4.6 ± 2.2 | 0.87 |
regulation | |||
LH (mIU/ml), down | 1.6 ± 0.9 | 2.7 ± 1.1 | <0.01 |
regulation | |||
17β-estradiol (E2) (pg/ml), | 26.4 ± 20 | 24.4 ± 14.5 | 0.31 |
down regulation | |||
rFSH treatment days | 11.7 ± 1.8 | 11.8 ± 1.5 | 0.64 |
Total rFSH dose (IU) | 2,479 ± 979 | 2,084 ± 648 | <0.05 |
E2 (pg/ml), day of hCG | 1,312 ± 629 | 1,516 ± 640 | 0.12 |
Total length of stimulation | 11.7 ±1.8 | 11.8 ± 1.5 | 0.64 |